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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not 2%
pirenzepine gel is effective in slowing the progression of myopia in children aged 7-12 years
old?
Study Design: Systemic review of three primary randomized controlled trials, which were
published in 2008, 2004, and 2005.
Data Sources: Multicenter, randomized double masked, placebo controlled, randomized
controlled trials (RCT) were found using PubMed, COCHRANE, and OVID databases.
Outcome measured: The outcome, slowing of myopia progression, was measured similarly in all
three trials. Progression of myopia was measured via changes in refractory status and spherical
equivalence specifically defined as >0.75D after 12 months of treatment.
Results: In all, the results found that children receiving 2% pirenzepine gel as opposed to placebo
did have a decrease in their progression of myopia. In the study Tan et al, it was reported that
myopia progression in the gel receiving group was averaged to be 0.47D while the placebo group
progressed 0.84D over the one year trial. The study done by Siatkowski et al discovered that
after a 2 year trial the group receiving treatment had a slower progression of myopia (0.58D)
than the placebo group (0.99D). Overall, pirenzepine was effective in slowing the progression of
myopia.
Conclusion: The results of the three RCT revealed that the use of 2% pirenzepine gel was safe
and slowed the progression of myopia when compared to the placebo group.
Key words: myopia, pirenzepine, progression
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Introduction
Myopia, also known as nearsightedness, is one of the most common ocular disorders. In
this condition the eye undertakes a myopic crescent anatomy therefore causing the eye to enlarge
and lengthen in the posterior segment1. The change in normal optic anatomy causes light rays to
be focused in front of the retina instead of the space on the retina. Axial myopia is due to the
cornea or lens curvature being too strong or the eye too long2. This causes images closer to be
viewed clearly and those further away to appear blurry. The exact cause of myopia is unknown
and there are no means to preventing it. Treatment options are available which include visual
training, bifocals, lenses, surgery, and pharmaceuticals3.
Myopia is among the leading causes of blindness and visual impairment in the world. It
has a high prevalence all over the world and has been found to affect women twice as much as
men. This condition is most often diagnosed in children between 8-12 years old and can progress
throughout a persons’ lifetime. It is estimated that worldwide there are 80 million myopic
children4. In the US, approximately 30% of the population has a form of myopia2. The National
Eye Institute conducted a study in 2008 which found that the prevalence of myopia had increased
66% in the US alone between 1971- 1972 and 1999-20045. There is not an exact estimate
available for world costs of myopia and its treatments. In the US the treatment of myopia is
predicted to cost an estimated $250 million per year2. Although the exact estimate for healthcare
visits per year is also unknown, millions of Americans receive some form of treatment for
myopia. It is estimated that 36 million Americans wear contact lens, 150 million Americans use
corrective eyewear and in 2010, 800,000 refractive surgical procedures were performed8.
Myopia is a refractory error with unknown etiology but hereditary and visual stressors are
two risk factors that contribute to its development. Most people that suffer from myopia can be
classified into two groups. Patient’s whose spherical equivalence (SE) is less than -6.0D would
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fall under the category of physiological or “school” myopia. This is the most prevalent form and
is considered a normal biological variation. In patients that have a SE greater than -6.0D are
categorized as high or pathological myopia. It is believed that this is caused when axial lengths
fail to stabilize during normal young adulthood. Pathological myopia is a progressive,
degenerative form of myopia that has a high incidence of retinal detachment and glaucoma 1.
The exact etiology of myopia is unknown but there are various known risk factors.
Physiological myopia is believed to be a response to stress on the eye. There is evidence that
increased time spent reading from teens to mid- 20s is related to school myopia1. Other factors,
such as race and ethnicity can contribute to nearsightedness. For instance, Asians and people of
Jewish decent have the highest prevalence while blacks have the lowest1.
Myopia can be corrected with glasses, contact lenses, bifocals, or surgery. Although
these treatments help correct myopia, they do not treat the underlying physiological condition.
Glasses and contact lenses are the easiest and fastest technique in correcting nearsightedness.
Contact lenses work by acting as the first refractive surface before light rays enter the eyes while
glasses or bifocals have a concave lens that allow for light to focus over a longer distance. This
allows for light to focus on the retina3. Refractive surgery usually involves a laser that
permanently alters the shape of the cornea. One type of surgery, known as PRK, removes a layer
of corneal tissue allowing for the cornea to flatten and light to focus on the retina. LASIK
procedure creates a thin flap on the cornea and removes corneal tissue and then returns the flap.
Also, orthokeratology is another treatment option for patients with myopia. This is a non-surgical
procedure where rigid or permeable contact lenses are worn at night to reshape the cornea.
Although this is a temporary treatment it can help correct mild to moderate myopia3. There is no
known preventative treatment for myopia. It is believed that visual training can help “control”
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myopia. These techniques may include muscle relaxation, eye massage, or biofeedback. There is
no evidence that these techniques help prevent or treat nearsightedness3.
The goal of using pirenzepine gel is to prevent the progression of myopia. By preventing
the progression of myopia, it decreases the chance for the patient to develop macular
degeneration, retinal detachment, and glaucoma1. Several studies have showed that the use of
muscarinic antagonists, such as atropine, which bind to M3 and M1 receptors, can slow the
progression of myopia in children. Pirenzepine is a selective M1 muscarinic receptor antagonist
that is believed to have fewer side effects than atropine. In animal trials, pirenzepine was able to
reduce deprivation-induced myopia and axial elongation. This drug is normally used to treat
dyspepsia and pediatric endocrine disorders and has a great safety profile6.
Objective
The objective of this selective evidence based medicine (EBM) review is to determine
whether or not 2% pirenzepine gel is effective in slowing the progression of myopia in children
aged 7-12 years old.
Methods
The three studies that are included in this EBM review are multicenter, double masked,
placebo controlled, randomized controlled trials (RCT). The criteria used for these studies were
based off of population and severity of nearsightedness. Patients were aged 7-12 with myopia
defined as a spherical equivalent (SE) of -0.75 to -4.00D and astigmatism of <1.00D in each
eye4, 6, 7. The treatment group received the intervention of 2% ophthalmic gel while the
experimental group received a placebo ophthalmic gel. These two groups were compared to
discover if an overall efficacy in slowing the progression of myopia was present and if use of the
gel was tolerable in children. Two of the three trials conducted the study for 1 year while the
remaining study was conducted for two years.
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Key words used in the searches were “pirenzepine”, “myopia”, and “progression.” The
databases used were COCHRANE, OVID, and PubMed. All articles were published in English
in peer reviewed journals. I researched the articles and each article was selected based on
relevance to my chosen topic and that each study included patient oriented outcomes (POEM).
My inclusion criteria encompassed randomized controlled trials published after 1996 with a
population aged 7-12 years. The exclusion criteria included children below age seven and greater
than age 12 or had already tried pirenzepine or surgical treatment. Summary of statistics used
were RRR, AAR, NNT, and p-values.
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Table 1: Demographics & Characteristics of included studies
Study
Type
#Pt Age Inclusion
Exclusion
s
(yrs) Criteria
Criteria

W/D

Intervention

Siatkowski
(2008)4

Double
Blind
RCT

84

8-12
y.o

Patients were
aged 8-12 and
had best
corrected
visual acuity
of >20/25 in
each eye

Patients with
current use of
contact lenses
or bifocals,
history of
ocular trauma,
disease or
surgery,
hypersensitivity
to topical
anesthetics,
mydriatics

1

2%
Pirenzepine
ophthalmic
gel twice
daily for two
years;
Placebo
ophthalmic
gel twice
daily for two
years

Siatkowski
(2004)7

Double
Blind
RCT

174

8-12
y.o

Patients were
aged 8-12 and
had best
corrected
visual acuity
of >20/25 in
each eye

29

2%
Pirenzepine
ophthalmic
gel twice
daily for 1
year; placebo
ophthalmic
gel twice a
day for 1 year

Tan
(2005)6

Double
Blind
RCT

353

6-12
y.o

Patients were
healthy, aged
6-12 and had
best corrected
visual acuity
of >20/25 in
each eye

Patients with
current use of
contact lenses
or bifocals,
history of
ocular trauma,
disease or
surgery,
hypersensitivity
to topical
anesthetics,
mydriatics
Patients with
current use of
contact lenses
or bifocals,
history of
ocular trauma,
disease or
surgery,
previous use of
atropine

23

2%
Pirenzepine
ophthalmic
gel twice
daily for 1
year; placebo
ophthalmic
gel twice a
day for 1 year
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Outcomes
The outcomes measured the progression of myopia. This was primarily measured by
changes in refractory status and spherical equivalent (SE). Refractory error is an error in the
ability of the eye to focus light and is a frequent reason for reduced visual activity. When
focusing does not work accurately, it results in blurred vision. Refractive error is related to the
ocular axial length therefore if there is in increase in axial length, there will be an increase in the
refractive error which causes a worsening of myopia. The SE is the refractory error but in
measurement form and is what optical prescriptions appear as. This measurement in diopters is
the unit of measurement of the optical power of lens. The higher the diopters or SE is, indicates
the severity of myopia.
Results
All three articles compared the use of pirenzepine with the use of a placebo to retard the
progression of myopia in patients aged 7-12. All three studies were double masked, placebocontrolled, RCTs. The identity of treatment was masked from the children, parents, and
investigators. The primary outcome measure for all three studies was myopia progression via
spherical equivalence. All patients were treated as outpatients.
Tan et al studied a total of 353 participants, aged 6 to 12 years with myopia defined as a
spherical equivalent of -0.75 to -4.00D and astigmatism of <1.00D in each eye. Patients
excluded from the study were ones with a spherical equivalent of >1.00 D, strabismus, current
use of contact lenses or bifocals and history of ocular surgery, trauma, chronic ocular disease, or
previous use of atropine for retarding myopia progression. Each patient underwent the study for
1 year as out patients and was randomly given either 2% pirenzepine gel or placebo gel packaged
in identical tubing. The medication was to be administered twice daily as a 6mm stripe in the culde-sac of the lower eyelid. Compliance monitoring started 6 months after the study had started
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with an electronic compliance monitoring device (ECMD). Patients had their SE measured at 3,
6, 9, and 12 months under cycloplegic refraction. At entry the mean SE was -2.4 + 0.9D. A
reduction in the progression of myopia over one year was observed where the mean increase of
myopia was 0.47D in the gel group and 0.84D increase in the placebo group (p <0.001, CI 95%,
placebo -3.29+ 1.02, gel -2.82+1.02 ) . The NNT for the one year study indicated that 4 patients
would need to be treated with 2% pirenzepine gel in order to have one fewer with progression of
myopia when compared to placebo (Table 2)6.
During the one year study, 11% of pirenzepine treated subjects discontinued the study
due to adverse events. There were 15 serious adverse events reported in 12 subjects, none of
which were ophthalmic in nature and all patients recovered. All side effects were mild to
moderate in nature and the most common of which was follicles/papillae (Table 3). The NNH
for this study was 9 meaning that for every 9 subjects treated with pirenzepine one additional
patient would experience any of the possible side effects (Table 4)6.
Table 2: Analysis of NNT among participants receiving 2% pirenzepine
Relative Risk Reduction
Absolute risk Reduction
Number needed to treat
(RRI)
(ARI)
(NNT)
-0.49
-0.28
-4
Table 3: Adverse side effects in participants receiving 2% pirenzepine gel vs. placebo6
Side Effect

% pirenzepine
treated subjects

% placebo treated
subjects

Follicles/papillae

59

14

Medication residue

52

49

Abnormality of accommodation

44

3

Cough

23

23

Abdominal Pain

9

1
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Table 4: Analysis of all adverse events among participants receiving pirenzepine
Number needed to harm
Relative Risk Increase (RRI)
Absolute risk Increase (ARI)
(NNH)
.11
.11
9
The two studies published by Siatkowski et al both had a population of healthy children,
aged 8 to 12 years old, with a SE of -0.75 to -4.00D and astigmatism of 1.00D or less. Each
study had the same inclusion and exclusion criteria (see Table 1). The study published in 2004
was conducted for 1 year and had a population size of 174 children. The subjects were randomly
given either 2% pirenzepine gel or placebo gel. Patients were instructed to use their “medication”
daily and keep their eyes closed 1 minute after use. Each patient was properly instructed with
demonstration from clinical staff. At 3, 6, 9, and 12 months the patients received eye exams and
the primary clinical outcome was measured. At study entry the mean SE refraction was -2.098 +
0.903 for the pirenzepine group and -1.933 + 0.825 for the placebo group. At 12 months the
mean increase in myopia in the pirenzepine group was 0.26D vs. 0.53D in the placebo group
(p<0.001, CI 95%, pirenzepine -2.42+ 0.99, placebo -2.41 + 1.04). The NNT for the one year
study indicated that 5 patients would need to be treated with 2% pirenzepine gel in order to have
one fewer with progression of myopia when compared to placebo (Table 5)7.
Table 5: Analysis of NNT among participants receiving pirenzepine in 1 and 2 year study
Relative Risk
Absolute risk
Number needed to
Study
Reduction (RRR)
Reduction (ARR)
treat (NNT)
Siatkowski 20047
-0.645
-0.20
-5
4
Siatkowski 2008
-0.46
-0.31
-4
The two year study published by Siatkowski et all (2008) had 84 participants all of whom
satisfactorily underwent the previous one year study. At the end of the two year study, the
pirenzepine group had a mean increase in myopia of 0.58D and 0.99D for the placebo group
(p=0.008, pirenzepine -2.84 + 1.04, placebo -2.82+ 1.13) . The NNT for the one year study
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indicated that 4 patients would need to be treated with 2% pirenzepine gel in order to have one
fewer with progression of myopia when compared to placebo (Table 5)4.
In the one year study, 13 patients (11%) of the pirenzepine group discontinued the study
due to adverse side effects while none of the placebo subjects had. The three most frequent
systemic events were headache and cold and flu syndrome. The most common ocular events
were mydriasis, erythema of the eyelids, and ocular itching (Table 6). The NNH for this study
was 9 meaning that for every 9 subjects treated with pirenzepine one additional patient would
experience any possible side effect (Table 7)7.
Table 6: Adverse side effects in participants receiving 2% pirenzepine gel vs. placebo in 1
year study7.
Side Effect

% pirenzepine treated
subjects

% placebo treated
subjects

P value

Headache

29

28

>0.99

Cold

20

40

.006

Flu syndrome

16

18

.83

Mydriasis

9

2

.10

Erythema, eyelids

7

4

.50

The two year study only had one patient drop out due to adverse side effects. This study
had the same ocular and systemic side effects as the one year study. The NNH for this study was
84 meaning that for every 84 subjects treated with pirenzepine one additional patient would
experience any one of the same side effects as the previous 1 year study (Table 7)4.
Table 7: Analysis of adverse events among participants receiving pirenzepine
Study
Relative Risk
Absolute risk
Number needed to
Increase (RRI)
Increase (ARI)
harm (NNH)
Siatkowski 20047
.11
.11
9
4
Siatkowski 2008
0.012
0.012
84
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Discussion
The three RCTs reviewed for this paper demonstrated the effectiveness of 2%
pirenzepine gel in comparison to placebo in retarding the progression of myopia in children. All
three studies mainly studied children from Asia but other studies have shown similar effects in
children in the United States9. Also, these RCT only looked at safety in children but other
studies have displayed tolerability and safety to the drug in adults4.
Pirenzepine hydrochloride is a “selective” muscarinic receptor antagonist that specifically
works on the M1 receptor. It has been used for years in Europe and Asia. It is normally used to
treat peptic ulcers and pediatric endocrine disorders. For ocular therapy, due to it being a
selective muscarinic antagonist, it is less active on the pupil and ciliary in the body. This
prevents dilation of the pupil and decreases the loss of ability to focus, which is commonly seen
with atropine use. It is commonly used in children >12 years and adults. It is well tolerated by
most patients with low incidence of anti-muscarinic effects. Anti-muscarinic side effects that
may present are dry mouth, blurred vision, drowsiness, nausea, loss of appetites, decreased
sexual desire. There are no black box warnings against the drug but it is not approved by the
FDA in the USA10.
Limitations were noted in the three RCT. Potential limitations found in the three studies
included lack of formal accommodation testing in the second year study and a slight difference
in baseline myopia between the pirenzepine and placebo group. Although the baseline difference
was not considered statistically significant it can still be seen as a potential limitation.
Additionally, there was no difference in family history between the placebo and pirenzepine
participants and all patients were of Asia ethnicity. Diversity in participants between each group
could allow for more information to be obtained about myopia. Also, all patients in the study had
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a SE that categorized them as having physiological myopia. The effects of the medication on
children with pathological myopia was not studied..
Conclusion
2% pirenzepine gel is an effective treatment for slowing the progression of myopia in
children. All three RCTs in this review were able to provide significant evidence that treatment
with this drug could reduce progression of myopia. Drug safety was also significantly proven as
each study only had mild to moderate adverse effects in a low percentage of patients.
There are only a few flaws in these studies. The most significant flaw was providing
proof of compliance during the study. Tan et al had started testing for compliance half way
through the studies with EMCD. By knowing compliance rates in both pirenzepine and placebo
groups can alter interpretations of statistical findings.
Myopia is a very common ocular disease and has been steadily increasing throughout
populations in the world. It is important to conduct future studies pertaining to slowing the
progression of myopia due to its increasing prevalence. In the future, studies of longer duration
should be done to discover optimal length of treatment. Also, future studies should include more
convenient and practical methods of drug administration, for example optic drops or systemic
pills. Future studies should also be done to analyze the effect of the medication on patients with
pathologic, progressive myopia. Future studies should also be done to analyze the effect of the
medication on patients with pathologic, progressive myopia. Finding a drug that is safe and
successful in slowing down the progression of myopia or even stopping it is an integral part to
finding a cure for myopia.
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